In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ventrica Inc.

Latest From Ventrica Inc.

The Death of Investing in Heart Surgery: An Exaggerated Demise

Over the past several years, new tools have helped interventional cardiologists capture patients who historically would have been candidates for surgery. Drug-eluting stents are apt to only increase this trend. These technology innovations have sparked the latest round of proclamations that there is no future in cardiac surgery since the sector's largest component--bypass--is waning, and that the only worthwhile coronary device investment opportunities lie in products with interventional applications. Yet cardiac surgery remains a major device opportunity. A significant increase in M&A activity and recent later-round financings by companies like Percardia and Converge indicate that investing in cardiac surgery start-ups remains alive and well, albeit with new challenges. Indeed, some investors believe that heart surgeons, traditionally conservative adopters of new technology, are now more receptive than ever to new devices and procedures because of the threat to their livelihoods posed by interventionalists' increased encroaching on surgeons' core patients.
Medical Device Business Strategies

Ventrica: Providing the Connection to Minimally Invasive Cardiac Surgery

In cardiac surgery, the slow shift to perform coronary bypass graft procedures off-pump has turned anastomotic device technology, a long dormant area of product development, into a hot subject at clinical meetings and attracted the attention of large and small device companies. One start-up, Ventrica, was founded to focus on a new bypass procedure, but shifted its emphasis to an important component of that procedure: an automated coronary anastomotic connector. The company's magnetic technology has given it a head-start on this hardest part of the bypass connector puzzle. Some industry experts and surgeons believe that an easy-to-use, reproducible, automated anastomotic device will boost adoption of off-pump bypass surgery, which has lagged far below initial expectations and will also be essential to the future of robotic surgery. Ventrica's challenge is to attract new groups of surgeons to this approach rather than simply preach to already-converted early adopters.
Medical Device Strategy

Cutting Out the Knots in Surgery

The needle-and-thread suturing process surgeons use to create anastomoses has been a staple in the OR, largely unchallenged for nearly a century. New developments in minimally invasive and endoscopic surgery, particularly in coronary bypass procedures, have created the need for a tissue-closure technique that can produce high-quality anastomoses in small spaces with limited visualization. As a result, anastomotic device technology, a long dormant area of product development, has become a hot subject at clinical meetings, and numerous companies, from major device firms to start-ups, are exploring a range of different approaches. Coalescent Surgical, a start-up, is one of the first to market in this area, with an anastomotic device that uses an approach different than its competitors--a proprietary self-closing clip that replaces traditional sutures. Coalescent's challenge: to gain acceptance from surgeons, who are notoriously slow adopters of new technology. The company is betting that the advantages of its device, combined with being first to market, will enable it to survive what appears will be a stampede of competitors, including major players that have superior resources and existing relationships with surgeons.
Medical Device North America

Beyond Bypass: Next Generation Coronary Revascularization

Traditional coronary artery bypass graft (CABG) surgery has been refined to be the most effective long-term treatment for occluded coronary arteries. Yet it remains a major surgical procedure that is traumatic for patients. Various minimally-invasive approaches to cardiac surgery have been developed but adoption rates are slow because these new procedures don't yet measure up to traditional CABG and because heart surgeons are slow adopters of new technology. Recent discoveries in coronary physiology have opened the door for new approaches to creating cardiac perfusion in a patient with occluded vessels. But this requires physicians to re-think what they were taught in medical school. One such approach, which involves direct vascularization from the ventricle, is being pursued by three companies: Percardia, HeartStent and Ventrica. Another company, TransVascular, is taking a broader approach by using the venous system to bypass arterial blockages. Approaches that require physicians to think differently about basic science, along with the tortuous clinical and regulatory path for new cardiac surgery devices and the cautious nature of cardiothoracic surgeons, present significant challenges to these start-up companies.
Medical Device Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ventrica Inc.
  • Senior Management
  • Mark Foley, Pres. & CEO
    Bill Kemper, CFO
  • Contact Info
  • Ventrica Inc.
    Phone: (510) 438-7100
    5055 Brandin Ct.
    Fremont, CA 94538